Table 1 Baseline characteristics
Variables | Ivermectin (N = 250) | Placebo (N = 251) |
|---|---|---|
Demographic characteristics | ||
Age years, mean (±SD) | 42.58 (15.29) | 42.40 (15.75) |
< 65 years, N (%) | 229 (91.6) | 231 (92.03) |
Weight Kg, mean (±SD) | 81.708 (18.507) | 81.313 (18.273) |
Dose μg/Kg/day, mean (±SD) | 192.37 (24.56) | 190.61 (23.93) |
Women, N (%) | 111 (44.4) | 126 (50.2) |
Hypertension, N (%) | 53 (21.3) | 66 (26.3) |
Diabetes mellitus, N (%) | 21 (8.4) | 27 (10.8) |
Smoker, N (%) | 27 (10.8) | 25 (10.0) |
Former smoker, N (%) | 72 (28.9) | 71 (28.3) |
Asthma, N (%) | 16 (6.4) | 20 (8.0) |
COPD, N (%) | 7 (2.8) | 7 (2.8) |
Previous myocardial infarction, N (%) | 3 (1.2) | 6 (2.4) |
Previous coronary angioplasty, N (%) | 3 (1.2) | 1 (0.4) |
Previous stroke, N (%) | 1 (0.4) | 4 (1.6) |
Heart failure, N (%) | 1 (0.4) | 3 (1.2) |
Cancer, N (%) | 4 (1.6) | 2 (0.8) |
Previous cancer, N (%) | 6 (2.4) | 4 (1.6) |
Any comorbidity, N (%) | 143 (57.66) | 149 (59.84) |
Symptoms / Swabs | ||
Symptomatic by COVID-19, N (%) | 240 (96.0) | 241 (96.0) |
Days from symptoms started to inclusion, median (IQR) | 4 (3–5) | 4 (3–6) |
Days from inclusion to swab 1, mean (±SD) | 3.26 (0.66) | 3.30 (0.71) |
Days from inclusion to swab 2, mean (±SD) | 9.99 (1.56) | 10.13 (1.69) |
Previous treatment | ||
Beta blockers, N (%) | 17 (6.8) | 21 (8.4) |
ACEI, N (%) | 13 (5.2) | 16 (6.4) |
ARB, N (%) | 28 (11.2) | 36 (14.3) |
Aspirin, N (%) | 14 (5.6) | 19 (7.6) |
Statins, N (%) | 22 (8.8) | 16 (6.4) |
Puff inhalation, N (%) | 10 (4.0) | 11 (4.4) |
Corticosteroids, N (%) | 12 (4.8) | 11 (4.4) |
Laboratory values | ||
Hematocrit %, mean (±SD) | 44.63 (5.12) | 43.29 (4.90) |
Hemoglobin g/dL, mean (±SD) | 14.79 (1.79) | 14.32 (1.73) |
White blood count, mean (±SD) | 5931.33 (1952.79) | 5550.96 (1778.07) |
Platelets /μL, mean (±SD) | 232,394.38 (66,306.41) | 222,032 (64,476.13) |
Creatinine mg/dL, mean (±SD) | 0.79 (0.25) | 0.81 (0.28) |
Urea g/L, median (IQR) | 0.30 (0.24–0.37) | 0.30 (0.24–0.38) |
AST U/L, median (IQR) | 27 (21–39) | 27 (20–41) |
ALT U/L, median (IQR) | 31 (18–50) | 29 (18–52) |
Alkaline phosphatase U/L, median (IQR) | 187 (151–234) | 187 (153.5–243.5) |
Total bilirrubin mg/dL, median (IQR) | 0.30 (0.20–0.42) | 0.30 (0.20–0.42) |
Vital signs | ||
V#1 Heart rate b/m, mean (±SD) | 83.18 (13.64) | 82.29 (13.41) |
V#1 Oxygen saturation %, mean (±SD) | 96.09 (3.16) | 96.31 (2.01) |
V#1 Axillary temperature °C, mean (±SD) | 36.15 (0.84) | 36.09 (0.80) |
V#2 Heart rate b/m, mean (±SD) | 82.05 (12.65) | 83.29 (13.35) |
V#2 Oxygen saturation %, mean (±SD) | 96.13 (2.28) | 96.04 (2.42) |
V#2 Axillary temperature °C, mean (±SD) | 35.99 (0.75) | 36.03 (0.77) |